RESUMEN
Metabolic syndrome (MetS) is a cluster of metabolic and cardiovascular (CV) risk factors including obesity and visceral adiposity, insulin resistance, dyslipidemia and hypertension contributing to CV mortality. The interface between the metabolic and immune systems has been of great interest recently. These interactions are regulated through genetics, nutritional status, and the intestinal microbiome. Alterations in the immune-metabolic cross-talk contribute to the development of autoimmune diseases. Adipokines exert a variety of metabolic activities contributing to the ethiopathogenesis of MetS and are involved in the regulation of both inflammatory processes and autoimmunity occurring in rheumatic diseases. Patients with autoinflammatory disease such as gout and those with autoimmune rheumatic diseases (ARD), such as systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid syndrome, ankylosing spondylitis and vasculitis among others, have increased prevalence of MetS. Despite recent advances in treatment of ARD, incidence of CVD remains high. MetS and altered secretion patterns of proinflammatory adipokines could be the link between CVDs and ARD. In addition, in ARD the activation of proinflammatory signalling pathways results in the induction of several biological markers of chronic inflammation contributing to CVD. In the present paper, we review recent evidences of the interactions between MetS and ARD, as well as novel therapeutic targets.
Asunto(s)
Autoinmunidad , Síndrome Metabólico , Enfermedades Reumáticas , Animales , Humanos , Síndrome Metabólico/inmunología , Síndrome Metabólico/terapia , Enfermedades Reumáticas/inmunología , Enfermedades Reumáticas/terapiaRESUMEN
BACKGROUND: Chronic relapsing inflammatory optic neuropathy (CRION) is a recurrent, idiopathic optic neuritis and is considered as a rare disease. OBJECTIVE: To describe the clinical course during long-term follow-up of patients with a diagnosis of CRION. METHODS: From a cohort of 1,735 patients with demyelinating disorders, we selected patients aged over 16 years with CRION according to current criteria. Demographic and clinical data, including initial presentation, symptoms, number of relapses, time delay in diagnosis, diagnostic methods, and treatment were obtained from clinical files. Infections, autoimmune diseases, and multiple sclerosis, among other conditions, were ruled out in all patients. RESULTS: We analyzed 30 patients with CRION: 24 women and six men, with mean age of 42.8±10.2 years, median disease course of 7.9 years (5.29-13.1), and median number of attacks of 2 (IQR 2-4). The initial manifestation was ocular pain in 97% and bilateral and sequential affection in 87%. Visual acuity was recovered in 50%, did not improve in 33%, and recovered incompletely in 17%. Antibodies against aquaporin-4 (AQP4-Abs) were negative in 73.3%. Magnetic resonance imaging of the brain was normal in 76.7%. None of the patients evolved to another demyelinating disease over time. Initial treatment was methylprednisolone in 100%, and plasmapheresis in 20%. Currently, all patients are on maintenance treatment with mycophenolate mofetil or rituximab with a decrease in relapsing rate. CONCLUSIONS: Diagnosis of CRION is challenging and should be kept in mind. Prompt diagnosis, adequate treatment and close follow-up are essential to prevent disabling sequelae in these patients.
Asunto(s)
Neuromielitis Óptica , Enfermedades del Nervio Óptico , Neuritis Óptica , Adulto , Acuaporina 4 , Autoanticuerpos , Enfermedad Crónica , Progresión de la Enfermedad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Enfermedades del Nervio Óptico/etiología , Enfermedades del Nervio Óptico/terapia , Neuritis Óptica/tratamiento farmacológico , Enfermedades Raras , RecurrenciaRESUMEN
Primary adrenal failure comprises an insufficient production of mineralocorticoids and glucocorticoids in the adrenal cortex. A rare manifestation of antiphospholipid syndrome (APS) is adrenal failure. The majority of patients with adrenal involvement in APS develop an irreversible cortisol deficiency and atrophy of the adrenal glands. Adrenal incidentalomas are adrenal masses larger than 1 cm that are discovered in the course of diagnostic evaluation or treatment for another medical condition. Its prevalence is calculated in 1.5-9% of individuals. We describe an exceptional case of a 23-year-old male patient with APS with persistent high levels of antiphospholipid antibodies (aPL) from the time of diagnosis, who developed Addison's disease as a manifestation of APS with atrophy of the adrenal glands, in whom an adrenal incidentaloma was developed later and was corroborated as an aldosterone-producing adenoma. Currently, the patient is asymptomatic and without manifestations of tumor recurrence. The protumoral effect of elevated and persistent aPL is discussed.
Asunto(s)
Enfermedad de Addison/inmunología , Neoplasias de las Glándulas Suprarrenales/inmunología , Insuficiencia Suprarrenal/inmunología , Síndrome Antifosfolípido/complicaciones , Neoplasias de las Glándulas Suprarrenales/diagnóstico , Neoplasias de las Glándulas Suprarrenales/etiología , Insuficiencia Suprarrenal/diagnóstico , Insuficiencia Suprarrenal/etiología , Anticuerpos Antifosfolípidos/sangre , Humanos , Masculino , Adulto JovenRESUMEN
ABSTRACT Background: Chronic relapsing inflammatory optic neuropathy (CRION) is a recurrent, idiopathic optic neuritis and is considered as a rare disease. Objective: To describe the clinical course during long-term follow-up of patients with a diagnosis of CRION. Methods: From a cohort of 1,735 patients with demyelinating disorders, we selected patients aged over 16 years with CRION according to current criteria. Demographic and clinical data, including initial presentation, symptoms, number of relapses, time delay in diagnosis, diagnostic methods, and treatment were obtained from clinical files. Infections, autoimmune diseases, and multiple sclerosis, among other conditions, were ruled out in all patients. Results: We analyzed 30 patients with CRION: 24 women and six men, with mean age of 42.8±10.2 years, median disease course of 7.9 years (5.29-13.1), and median number of attacks of 2 (IQR 2-4). The initial manifestation was ocular pain in 97% and bilateral and sequential affection in 87%. Visual acuity was recovered in 50%, did not improve in 33%, and recovered incompletely in 17%. Antibodies against aquaporin-4 (AQP4-Abs) were negative in 73.3%. Magnetic resonance imaging of the brain was normal in 76.7%. None of the patients evolved to another demyelinating disease over time. Initial treatment was methylprednisolone in 100%, and plasmapheresis in 20%. Currently, all patients are on maintenance treatment with mycophenolate mofetil or rituximab with a decrease in relapsing rate. Conclusions: Diagnosis of CRION is challenging and should be kept in mind. Prompt diagnosis, adequate treatment and close follow-up are essential to prevent disabling sequelae in these patients.
RESUMEN Antecedentes: Neuropatía óptica inflamatoria crónica recidivante (CRION) es una neuritis óptica idiopática recurrente, considerada una enfermedad rara. Objetivo: Describir la evolución clínica durante el seguimiento a largo plazo de pacientes con diagnóstico de CRION. Métodos: De una cohorte de 1.735 pacientes con trastornos desmielinizantes, seleccionamos pacientes mayores de 16 años con diagnóstico de CRION según los criterios actuales. Datos demográficos y clínicos, incluyendo presentación inicial, síntomas, recaídas, tiempo de retraso diagnóstico, métodos de diagnóstico y tratamiento se obtuvieron de los archivos clínicos. Se descartaron en todos los pacientes infecciones, enfermedades autoinmunes, esclerosis múltiple, entre otras condiciones. Resultados: Se analizaron 30 pacientes con diagnóstico de CRION: 24 mujeres y 6 hombres, edad media de 42,8±10,2 años, mediana del curso de la enfermedad de 7,9 años (5,2-13,1), mediana del número de recaídas 2 (IQR 2-4). La manifestación inicial fue dolor ocular en el 97% y afección bilateral y secuencial en el 87%. La agudeza visual mejoró en el 50%, sin recuperación en el 33% y con restauración incompleta en el 17%. Los anticuerpos contra acuaporina-4 (AQP4-Abs) fueron negativos en el 73,3%. La resonancia magnética cerebral fue normal en el 76,7%. Ningún paciente evolucionó hacia otra enfermedad desmielinizante en el seguimiento. El tratamiento inicial fue metilprednisolona en el 100%, y plasmaféresis en el 20%. Actualmente, todos los pacientes están en tratamiento de mantenimiento con micofenolato de mofetilo o rituximab con disminución de la tasa de recaídas. Conclusiones: El diagnóstico de CRION representa un desafío y debe tenerse en cuenta. El diagnóstico oportuno, tratamiento adecuado y seguimiento estrecho son fundamentales para evitar secuelas invalidantes.